Characteristics and response to treatment among aboriginal people receiving heroin-assisted treatment

Canadian Journal of Public Health

Volumn 101, Issue 3, 2010, Pages 210-212

  Oviedo Joekes, Eugenia ^a,b   Guh, Daphne ^b   Marsh, David C ^a,b,c,d   Brissette, Suzanne ^e   Nosyk, Bohdan ^b   Krausz, Michael ^a,b   Anis, Aslam ^a,b   Christian, Wayne M ^f   Spittal, Patricia ^a,b   Schechter, Martin T ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^c VANCOUVER COASTAL HEALTH   (Canada)

^d UNIVERSITY OF VICTORIA   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f Splats'in/Secwepemc Nation   (Canada)

Author keywords

Aboriginal; Canada; Diacetylmorphine; Hydromorphone; Injectable; Methadone; Opioid dependence; Oral; Substitution treatment

Indexed keywords

DIAMORPHINE; HYDROMORPHONE; METHADONE; NARCOTIC AGENT;

ADULT; AMERICAN INDIAN; ARTICLE; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESKIMO; FEMALE; HEROIN DEPENDENCE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; BRITISH COLUMBIA; FEMALE; HEROIN; HEROIN DEPENDENCE; HUMANS; HYDROMORPHONE; INDIANS, NORTH AMERICAN; INUITS; MALE; METHADONE; NARCOTICS; TREATMENT OUTCOME;

EID: 77957288260     PISSN: 00084263     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03404375     Document Type: Article

References (17)

1. Gibson DR, Brand R, Anderson K, Kahn JG, Perales D, Guydish J. Two- to sixfold decreased odds of HIV risk behavior associated with use of syringe exchange. J Acquir Immune Defic Syndr 2002;31:237-42.
2. Termorshuizen F, Krol A, Prins M, van Ameijden EJ. Long-term outcome of chronic drug use: The Amsterdam Cohort Study among Drug Users. Am J Epidemiol 2005;161:271-79.
3. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, Garciá de Olalla P, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and AIDS in a cohort of heroin users in Spain. Addiction 2005;100:981-89.
4. van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: Two randomised controlled trials. BMJ 2003;327:310.
5. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: A follow-up study. Lancet 2001;358:1417-23.
6. March JC, Oviedo-Joekes E, Perea-Milla E, Carrasco F. Controlled trial of prescribed heroin in the treatment of opioid addiction. J Subst Abuse Treat 2006;31:203-11.
7. Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D. Heroinassisted treatment for opioid dependence: Randomised controlled trial. Br J Psychiatry 2007;191:55-62.
8. Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, et al. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med 2009;361:777-86.
9. PHAC. HIV/AIDS Among Aboriginal Peoples in Canada: A continuing concern. HIV/AIDS Epi Update. Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, 2006.
10. Kerr T, Marsh D, Li K, Montaner J, Wood E. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Drug Alcohol Depend 2005;80:329-35.
11. Oviedo-Joekes E, Nosyk B, Marsh D, Guh D, Brissette S, Gartry C, et al. Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI Study. Clinical Trials 2009;6:261-71.
12. Oviedo-Joekes E, Nosyk B, Brissette S, Chettiar J, Schneeberger P, Marsh DC, et al. The North American Opiate Medication Initiative (NAOMI): Profile of Participants in North America's First Trial of Heroin-Assisted Treatment. J Urban Health 2008;85:812-25.
13. Health Canada. Best practices in methadone maintenance treatment. Ottawa, ON: Minister of Public Works and Government Services Canada, 2002.
14. Kokkevi A, Hartgers C. EuropASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence. Eur Addict Res 1995;1:208-10.
15. Nosyk B, MacNab YC, Sun H, Fischer B, Marsh DC, Schechter MT, et al. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol 2009;170:783-92.
16. Craib KJ, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ 2003;168:19-24.
17. Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2004;CD004145.